BIOMAT Database Logo BIOMAT Database Logo

An affordable HIV-1 drug resistance monitoring method for resource limited settings. 2014

Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
Africa Centre for Health and Population Studies, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted drug resistance to track transmission of viral strains already resistant to ART is also critical. Unfortunately, drug resistance testing is still not readily accessible in resource limited settings, because genotyping is expensive and requires sophisticated laboratory and data management infrastructure. An open access genotypic drug resistance monitoring method to manage individuals and assess transmitted drug resistance is described. The method uses free open source software for the interpretation of drug resistance patterns and the generation of individual patient reports. The genotyping protocol has an amplification rate of greater than 95% for plasma samples with a viral load >1,000 HIV-1 RNA copies/ml. The sensitivity decreases significantly for viral loads <1,000 HIV-1 RNA copies/ml. The method described here was validated against a method of HIV-1 drug resistance testing approved by the United States Food and Drug Administration (FDA), the Viroseq genotyping method. Limitations of the method described here include the fact that it is not automated and that it also failed to amplify the circulating recombinant form CRF02_AG from a validation panel of samples, although it amplified subtypes A and B from the same panel.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D060005 Genotyping Techniques Methods used to determine individuals' specific ALLELES or SNPS (single nucleotide polymorphisms). Genotype Assignment Methodology,Genotype Calling Methods,Genotype Determination Methods,Assignment Methodologies, Genotype,Assignment Methodology, Genotype,Calling Method, Genotype,Calling Methods, Genotype,Determination Method, Genotype,Determination Methods, Genotype,Genotype Assignment Methodologies,Genotype Calling Method,Genotype Determination Method,Genotyping Technique,Method, Genotype Calling,Method, Genotype Determination,Methodologies, Genotype Assignment,Methodology, Genotype Assignment,Methods, Genotype Calling,Methods, Genotype Determination,Technique, Genotyping,Techniques, Genotyping
D019295 Computational Biology A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories for solving biological problems including manipulation of models and datasets. Bioinformatics,Molecular Biology, Computational,Bio-Informatics,Biology, Computational,Computational Molecular Biology,Bio Informatics,Bio-Informatic,Bioinformatic,Biologies, Computational Molecular,Biology, Computational Molecular,Computational Molecular Biologies,Molecular Biologies, Computational
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus
D020133 Reverse Transcriptase Polymerase Chain Reaction A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols. Polymerase Chain Reaction, Reverse Transcriptase,Reverse Transcriptase PCR,PCR, Reverse Transcriptase,Transcriptase PCR, Reverse
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings.
February 2023, AIDS research and therapy,
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings.
January 2019, F1000Research,
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
May 2007, AIDS (London, England),
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
Assessments of HIV drug resistance mutations in resource-limited settings.
April 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
Antiretroviral drug resistance in resource-limited settings.
October 2012, Lancet (London, England),
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
A model for reduced HIV-1 viral load monitoring in resource-limited settings.
January 2013, Journal of the International Association of Providers of AIDS Care,
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.
January 2011, PloS one,
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
HIV-1 viral load assays for resource-limited settings.
October 2006, PLoS medicine,
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
Pooled nucleic acid testing strategy for monitoring HIV-1 treatment in resource limited settings.
August 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Justen Manasa, and Siva Danaviah, and Sureshnee Pillay, and Prevashinee Padayachee, and Hloniphile Mthiyane, and Charity Mkhize, and Richard John Lessells, and Christopher Seebregts, and Tobias F Rinke de Wit, and Johannes Viljoen, and David Katzenstein, and Tulio De Oliveira
HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies.
June 2021, Viruses,
Copied contents to your clipboard!